Fig. 2From: Association between the XRCC1 polymorphisms and clinical outcomes of advanced NSCLC treated with platinum-based chemotherapy: a meta-analysis based on the PRISMA statementForest plots of XRCC1 Arg194Trp polymorphisms and objective response in platinum-based chemotherapy by different allele contrast models. a homozygous model, b recessive model, c allele comparison. An OR >1 (or <1) indicates that the 194Arg is more (or less) likely to show response than 194TrpBack to article page